Get started
Author

Stephanie Valer Seremetis

Observed names: S Seremetis, S V Seremetis, S. SEREMETIS, S. Seremetis, S. V. SEREMETIS, S.V Seremetis, S.V. Seremetis, STEPHANIE SEREMETIS, STEPHANIE V. SEREMETIS, Seremetis, Stephanie, Stephanie Seremetis, Stephanie V Seremetis, Stephanie V. Seremetis, Stephanie V. Seremetis
Observed institutions: Tulane University, Brigham and Women's Hospital, Mount Sinai Beth Israel, St. Jude Children's Research Hospital, Mount Sinai Health System, Mount Sinai Hospital, Children's Hospital Los Angeles, Howard Hughes Medical Institute, Novo Nordisk (Denmark), Princeton University, Washington University in St. Louis, Saint Louis University Hospital, NYU Langone Health, Novo Nordisk (United States), Indiana Hemophilia and Thrombosis Center, New York University Langone Orthopedic Hospital, Saint Louis University, New York University, Icahn School of Medicine at Mount Sinai
OpenAlex ID: A5110154787
Childhood emotional abuse and neglect as predictors of psychological and physical symptoms in women presenting to a primary care practice
2003 · Ilyse L Spertus, Rachel Yehuda, et al. · Child Abuse & Neglect · 509
Single 270 μg kg−1‐dose rFVIIa vs. standard 90 μg kg−1‐dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison
2007 · G. YOUNG, F. E. SHAFER, et al. · Haemophilia · 155
Internalization of human immunodeficiency virus type I and other retroviruses by megakaryocytes and platelets
1990 · D Zucker-Franklin, S Seremetis, et al. · Blood · 145
PDF
Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal
2007 · M. J. SUMNER, B. D. GELDZILER, et al. · Haemophilia · 138
Growth- and tumor-promoting effects of deregulated BCL2 in human B-lymphoblastoid cells.
1989 · G Nunez, M Seto, et al. · Proceedings of the National Academy of Sciences · 131
Biochemistry and expression of myelomonocytic antigens.
1986 · S M Goyert, E M Ferrero, et al. · The Journal of Immunology · 127
Pharmacokinetic analysis of plasma‐derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B
2002 · Bruce M. Ewenstein, J. Heinrich Joist, et al. · Transfusion · 101
High frequency of clonal immunoglobulin or T cell receptor gene rearrangements in acute myelogenous leukemia expressing terminal deoxyribonucleotidyltransferase.
1987 · S V Seremetis, P G Pelicci, et al. · The Journal of Experimental Medicine · 90
PDF
Monoclonal antibodies to the human CSF-1 receptor (c-fms proto-oncogene product) detect epitopes on normal mononuclear phagocytes and on human myeloid leukemic blast cells
1989 · RA Ashmun, AT Look, et al. · Blood · 89
PDF
Transformation and Plasmacytoid Differentiation of EBV-Infected Human B Lymphoblasts by ras Oncogenes
1989 · Stephanie Seremetis, Giorgio Inghirami, et al. · Science · 88
Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A : safety and efficacy
2013 · S. R. Lentz, M. Misgav, et al. · Haemophilia · 84
Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status
1993 · S.V Seremetis, L.M Aledort, et al. · The Lancet · 73
Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program
2019 · Gallia G. Levy, Elina Asikanius, et al. · Journal of Thrombosis and Haemostasis · 66
Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery
2007 · Prasad Mathew, Leonard Valentino, et al. · Thrombosis and Haemostasis · 65
Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A : safety, efficacy and pharmacokinetics
2013 · R. Kulkarni, F. A. Karim, et al. · Haemophilia · 61
TdT-positive acute leukemia with monocytoid characteristics: clinical, cytochemical, cytogenetic, and immunologic findings
1984 · J Cuttner, S Seremetis, et al. · Blood · 58
PDF
Major and Minor Classifications for Surgery in People With Hemophilia: A Literature Review
2017 · Luigi Piero Solimeno, Miguel A. Escobar, et al. · Clinical and Applied Thrombosis/Hemostasis · 55
PDF
Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate
1994 · J.J. Goedert, C.S. Rabkin, et al. · The Lancet · 54
Safety update on the use of recombinant activated factor VII in approved indications
2015 · Ellis J Neufeld, Claude Négrier, et al. · Blood Reviews · 50
Long Term Evaluation of Septic Arthritis in Hemophilic Patients
1996 · Marvin S. Gilbert, Louis M. Aledort, et al. · Clinical Orthopaedics and Related Research · 39
Evidence for the separate molecular expression of four distinct polymorphic Ia epitopes on cells of DR4 homozygous individuals
1984 · Takashi Toguchi, Gerd Burmester, et al. · Human Immunology · 30
The use of recombinant activated factor VII in patients with acquired haemophilia
2015 · Andreas Tiede, Kagehiro Amano, et al. · Blood Reviews · 26
Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion
2003 · Erika Martin, Jan Kuhn, et al. · Thrombosis and Haemostasis · 26
Risk Mitigation Strategy for Concizumab Clinical Trials after Pause Due to Non-Fatal Thrombotic Events
2020 · Stephanie Valer Seremetis, Katarina Cepo, et al. · Blood · 24
Definition of a possible genetic basis for susceptibility to acute myelogenous leukemia associated with the presence of a polymorphic Ia epitope.
1985 · S Seremetis, J Cuttner, et al. · Journal of Clinical Investigation · 24
PDF
Works count: 72
Citation count: 2,558
H-index: 24
I10-index: 36
Year
Topic
Type